Medicines intelligence is the starting point. The wider ambition connects biological research, formulations, space systems, AI and robotics through distinct businesses and programmes. VARUNÉ Group is the founder-led portfolio brand; it does not establish a parent–subsidiary structure.
An operating company and a controlled product-development programme. Neither stage is used as shorthand for deployment, customers or clinical outcomes.
The pharmaceutical company through which Varun is building systems for evidence, human judgement and accountable follow-through in medicines work.
Present evidence
Incorporated in Scotland on 4 August 2025; current work includes PHARMORIS development.
NEUVIOR PHARMACEUTICALS LTD
Companies House · SC857853
An operating company is not evidence of customers, deployment or clinical outcomes.
A staff-facing system intended to connect reviewable evidence, authorised decisions and accountable follow-through.
Present evidence
A controlled, non-production development programme. NEUVIOR has been selected for non-dilutive support for defined R&D project work.
Not presented as deployed, clinically validated, NHS-backed or production-ready.
Biosystems brings together five peer research pillars. Intelligence explores AI and robotics. Labs, operated by NEUVIOR, develops the ambition across medicines, formulations, personal care and longer-range manufacturing plans.
A proposed research direction connecting how biological systems keep time, age, repair and respond to interventions. The five pillars are peers; no one pillar defines the whole business.
Present evidence
A registered company, incorporated on 30 October 2025; its current legal name took effect on 1 September 2026.
VARUNÉ BIOSYSTEMS LTD
Companies House · 16820832
Proposed research interests do not establish validated capability, products or outcomes.
Exploring how intelligence and robotics could address complex real-world problems, with human responsibility built into the direction from the start.
Present evidence
A registered company, incorporated in Scotland on 4 August 2025, with an exploratory AI and robotics direction.
VARUNÉ INTELLIGENCE LTD
Companies House · SC857816
No deployed product, customer or partnership is claimed; shared leadership does not establish ownership of other portfolio outputs.
A programme spanning medicines, novel formulations, generics, skincare and personal care, fragrance and sensory research, with longer-range manufacturing and facility planning.
Present evidence
A predevelopment programme operated by NEUVIOR PHARMACEUTICALS LTD (SC857853). VARUNÉ Labs is not a separate legal company or a Biosystems subsidiary.
No confirmed facility, owned laboratory, manufacturing capability or regulated activity is claimed.
VARUNÉ Space Systems is the current exploratory, precommercial space direction. It gives the ambition a clear home while the research questions and future development path take shape.
The current VARUNÉ space direction: exploratory, precommercial work towards future space systems and the questions that must be answered before they can be built.
Present evidence
A registered company, incorporated in Scotland on 4 August 2025; its current legal name took effect on 1 September 2026.
VARUNÉ SPACE SYSTEMS LTD
Companies House · SC857817
An exploratory direction is not a confirmed mission, payload, partnership or flight capability.
The future stays credible when the rules for reaching it are visible.
A claim should survive a sceptical reader, a source check and the passage of time.
Software may organise evidence and options; accountable people retain judgement and approval.
NEUVIOR and PHARMORIS come first. Future theses advance only when evidence earns the next gate.
Unknown remains unknown. Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.